1 minute reading
1 minute reading
The inspection, conducted by the US Food and Drug Administration between September 19 and 26, found lapses in quality control procedures and the use of an unregistered testing laboratory outside of official facilities.
The USFDA also noted that finished active pharmaceutical ingredients intended for the U.S. market were being released into an off-site warehouse without proper documentation. Other procedural deficiencies were cited, including the failure to record out-of-specification results from the unregistered laboratory, raising questions about the company’s compliance with regulatory standards.
Hetero Labs is a major player in the active pharmaceutical ingredient market and the second largest in the antiretroviral segment. Experts suggest that any escalation in regulatory measures could disrupt supplies to the Nakkapalli plant, potentially benefiting competitors such as Laurus Labs and Aurobindo Pharma.
The market is now closely monitoring Hetero Labs’ Form 483 response and subsequent USFDA actions, which will determine the long-term impact on the company’s operations and supply chain.
(Edited by: Ajay Vaishnav)
Sony's next console (presumably the PS6) will arrive in "a few years", according to someone I believe is making this…
Week 6 of the NFL season brings the return of two threads.Editor's Choice2 RelatedOn “Monday Night Football,” the Atlanta Falcons…
Your support helps us tell the storyFrom reproductive rights to climate change to Big Tech, The Independent is on the…
Since then, shares have rebounded, mainly after the company reported strong second-quarter results in July, and have gained more than…
This week, General Motors held an event where they announced a host of new details about its upcoming entry-level electric…
Older men in Los Angeles County thought they had found a date.What they ended up discovering was that their supposed…